Cargando…

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications

Despite their high potential for drug-drug interactions (DDI), clinical DDI studies of antiretroviral drugs (ARVs) are often lacking, because the full range of potential interactions cannot feasibly or pragmatically be studied, with some high-risk DDI studies also being ethically difficult to undert...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stader, Felix, Kinvig, Hannah, Battegay, Manuel, Khoo, Saye, Owen, Andrew, Siccardi, Marco, Marzolini, Catia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021627/ https://www.ncbi.nlm.nih.gov/pubmed/29686151 http://dx.doi.org/10.1128/AAC.00717-18

Ejemplares similares

Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study
por: Bettonte, Sara, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling to Support the Clinical Management of Drug–Drug Interactions With Bictegravir
por: Stader, Felix, et al.
Publicado: (2021)

Impact of Obesity on the Drug–Drug Interaction Between Dolutegravir and Rifampicin or Any Other Strong Inducers
por: Berton, Mattia, et al.
Publicado: (2023)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
por: Marzolini, Catia, et al.
Publicado: (2022)

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
por: Grañana-Castillo, Sandra, et al.
Publicado: (2022)

Magnitude of Drug–Drug Interactions in Special Populations
por: Bettonte, Sara, et al.
Publicado: (2022)

Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates
por: Bettonte, Sara, et al.
Publicado: (2023)

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
por: Moss, Darren M., et al.
Publicado: (2015)

Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs
por: Courlet, Perrine, et al.
Publicado: (2021)

Physiologically Based Pharmacokinetic Modelling to Identify Physiological and Drug Parameters Driving Pharmacokinetics in Obese Individuals
por: Berton, Mattia, et al.
Publicado: (2022)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Prescribing issues in older adults living with HIV: thinking beyond drug–drug interactions with antiretroviral drugs
por: Livio, Françoise, et al.
Publicado: (2019)

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions
por: Back, David, et al.
Publicado: (2020)

Drug–Drug Interactions with Antiretroviral Drugs in Pregnant Women Living with HIV: Are They Different from Non-Pregnant Individuals?
por: Bukkems, Vera E., et al.
Publicado: (2020)

Prevalence of Potential Drug-Drug Interactions Involving Antiretroviral Drugs in a Large Kenyan Cohort
por: Kigen, Gabriel, et al.
Publicado: (2011)

Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
por: Hsu, Po-Yao, et al.
Publicado: (2021)

Polypharmacy, Drug–Drug Interactions, and Inappropriate Drugs: New Challenges in the Aging Population With HIV
por: Courlet, Perrine, et al.
Publicado: (2019)

A Comprehensive Framework for Physiologically‐Based Pharmacokinetic Modeling in Matlab
por: Stader, Felix, et al.
Publicado: (2019)

Drug–Drug Interactions in People Living With HIV at Risk of Hepatic and Renal Impairment: Current Status and Future Perspectives
por: Cottura, Nicolas, et al.
Publicado: (2022)

Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection
por: Seden, Kay, et al.
Publicado: (2017)

Repository Describing the Anatomical, Physiological, and Biological Changes in an Obese Population to Inform Physiologically Based Pharmacokinetic Models
por: Berton, Mattia, et al.
Publicado: (2022)

Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects
por: Mallikaarjun, Suresh, et al.
Publicado: (2016)

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Effect of antiepileptic drug comedication on lamotrigine concentrations
por: Lovrić, Mila, et al.
Publicado: (2018)

Physiologically‐Based Pharmacokinetic Modeling Combined with Swiss HIV Cohort Study Data Supports No Dose Adjustment of Bictegravir in Elderly Individuals Living With HIV
por: Stader, Felix, et al.
Publicado: (2021)

Cobicistat: A case of mislabelled drug‐drug interaction risk?
por: Burger, David M., et al.
Publicado: (2020)

Prevalence and management of drug–drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study
por: Schlaeppi, C, et al.
Publicado: (2019)

PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2021)

Sex Differences in Lopinavir Concentrations and Occurrence of Marked QTc Prolongation Episodes in Patients with COVID-19
por: Marzolini, Catia, et al.
Publicado: (2020)

Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19
por: Girardin, François, et al.
Publicado: (2022)

Correction to: Predicting Drug–Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling
por: Montanha, Maiara Camotti, et al.
Publicado: (2022)

Editorial: Drug-drug interactions in pharmacology
por: Pichini, Simona, et al.
Publicado: (2023)

Risk of Drug-Drug Interactions in Out-Hospital Drug Dispensings in France: Results From the DRUG-Drug Interaction Prevalence Study
por: Létinier, Louis, et al.
Publicado: (2019)

Opioid Drug-Drug-Drug Interactions and Unintentional Traumatic Injury: Screening to Detect Three-Way Drug Interaction Signals
por: Acton, Emily K., et al.
Publicado: (2022)

Drug–Drug Interactions Based on Pharmacogenetic Profile between Highly Active Antiretroviral Therapy and Antiblastic Chemotherapy in Cancer Patients with HIV Infection
por: Berretta, Massimiliano, et al.
Publicado: (2016)

Screening for severe drug-drug interactions in patients with multiple sclerosis: A comparison of three drug interaction databases
por: Hecker, Michael, et al.
Publicado: (2022)

Drug-Drug Interactions at Organic Cation Transporter 1
por: Zhou, Shiwei, et al.
Publicado: (2021)

The Challenge of Potential Drug–Drug Interactions Among People Living With HIV on Antiretroviral Therapy: A Cross-Sectional Study in Selected Provinces in China
por: Xia, Huan, et al.
Publicado: (2020)

Dexamethasone is a dose-dependent perpetrator of drug–drug interactions: implications for use in people living with HIV
por: Jacobs, Tom G, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f6tso4tg0hvbpeporg68o1jf0m